Navigation Links
Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
Date:6/9/2009

NEW YORK, June 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that on June 5, 2009, it received a letter from the NASDAQ Listing Qualifications Hearings Panel granting the Company an extension through August 31, 2009, to regain compliance with Nasdaq Listing Rule 5550(b), which requires the Company to have a minimum of $2,500,000 in stockholders' equity, or $35,000,000 market value of listed securities, or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years, for continued listing on The Nasdaq Capital Market.

The Company expects to be able to comply with Nasdaq Listing Rule 5550(b) for continued listing on The Nasdaq Capital Market by August 31, 2009; however, there can be no assurance that the Company will be able to do so. Failure to comply with the conditions for listing could result in the delisting of the Company's common stock from The Nasdaq Capital Market.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of oth
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
3. Keryx Biopharmaceuticals Receives Nasdaq Notification
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
5. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
7. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
9. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
10. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
11. MedApps Receives FDA Clearance on a New Way to Bring Cost-Effective Remote Health Monitoring to More People
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... records to understand the best available treatment for patients, ... and less costly for taxpayers than the existing clinical ... Professor van Staa, carried out while he was a ... who is now based at The University of Manchester,s ... ( HTA ) today (Friday 11 July) looked ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... the risk for stroke, a new study suggests. The ... a stroke or a transient ischemic attack (TIA) by ... or TIA risk by 59 percent. And hostility doubled the ... by a temporary blockage of blood flow to the brain. ...
(Date:7/11/2014)... conducted at Aarhus University has revealed that people who ... only half as likely as their urban counterparts to ... and Crohn,s disease. The study findings have recently been ... , "It is extremely exciting that we can now ... classic inflammatory diseases appear to depend on the environment ...
(Date:7/11/2014)... As reported by Forbes in the article Robert Downey ... (6/30), Indino Downey has reportedly been arrested after being ... with. His father, well-known actor Robert Downey Jr. believes ... may have something to do with his addiction struggles. ... and 1990s for substance abuse before finally getting clean ...
(Date:7/11/2014)... July 11, 2014 Having experienced mental illness ... member of mental hospital staff, Roger Grainger gives readers an ... in his new book, “You Never Get Out.” , According ... the United Kingdom will experience some kind of mental health ... still needs to take a look at the way mental ...
Breaking Medicine News(10 mins):Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Growing up on a livestock farm halves the risk of inflammatory bowel diseases 2Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2
... for "tennis elbow" but needs to be injected properly ... CMAJ ( Canadian Medical Association Journal ) ... a randomized controlled trial of 48 patients, was performed ... University of Medical Sciences that serves patients from all ...
... HACKENSACK, N.J. (April 26, 2010, 4 p.m. EDT) Myelodysplastic syndromes ... are nearly five times more common in seniors than previously ... John Theurer Cancer Center at Hackensack University Medical Center. ... patients are at much higher risk for heart attack, diabetes ...
... predict which are most likely to be good candidates ... News) -- U.S. researchers have developed a new tool ... potential organ donors, a development that could potentially boost ... damage are often good candidates for organ donation when ...
... diabetes now widespread, CDC survey finds , MONDAY, April ... adults have either high blood pressure, high cholesterol or ... stroke and other cardiovascular problems, a new government survey ... Health and Nutrition Examination Survey (NHANES) 1999-2006 shows that ...
... VA - The American Society of Pediatric Otolaryngology (ASPO) ... 2, during the 2010 Combined Otolaryngology Spring Meetings (COSM) ... Las Vegas, NV. During the ASPO meeting, ... scientific sessions featuring expert panelists will be presented focusing ...
... Readers are ... his interest and research on improving ones state of life. This book helps readers to ... strives to touch all walks of life. , ... Washington, D.C. (Vocus) April 26, 2010 -- Thomas Finn is ...
Cached Medicine News:Health News:Botulinum injection provides relief of tennis elbow 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 3Health News:Test Spots Potential Organ Donors Among Coma Patients 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 3Health News:Scientific meeting will host new research in children's ear, nose and throat health 2Health News:Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15 2
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... June 4 Mylan Inc. (Nasdaq: MYL ) ... approval from the U.S. Food and Drug Administration (FDA) for its ... and 800 mg, the generic version of Pfizer,s Neurontin® Tablets for ... will be distributed by Mylan Pharmaceuticals Inc. , ...
... June 4 Syndax Pharmaceuticals, Inc., a ... Phase 2, open-label ENCORE 303 trial in post-menopausal women ... were progressing on aromatase inhibitor (AI) therapy. Safety and ... a poster at the American Society of Clinical Oncology ...
Cached Medicine Technology:Mylan Receives Approval for Generic Version of Neurontin® Tablets 2Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 2Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 3Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 4
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
... VACUETTE® erythrocyte sedimentation rate analysers, which ... new generation unites the well-established advantages ... range of additional innovations which guarantee ... sedimentation rate. Cost effectiveness is an ...
... ESR analyzer that brings about ... pipettes. Up to 40 test ... or bach, with automated mixing. ... for back-up support or to ...
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: